TRT and high hematocrit: separating real risk from bro science

What did @the.tudca.king actually say?

The creator makes two core claims: first, that testosterone raises red blood cell count and hematocrit in virtually everyone, even at low doses, creating a heart risk. Second, that a commercial supplement called Hemophilol contains ingredients "clinically shown" to address blood thickness, circulation, blood pressure, clotting, and hematocrit. The video ends with a direct product link.

To be clear about the structure here: the creator sets up a fear-based framing, "everything you've been told about testosterone is a big fucking lie," then positions a product as the solution doctors supposedly won't tell you about. That is a sales funnel dressed as health education. Recognizing that framing matters before evaluating the individual claims, some of which have real science behind them and some of which do not.

Does the science back this up?

The hematocrit elevation claim is well-supported. The supplement-as-fix claim is not, at least not to the degree presented.

Testosterone does stimulate erythropoiesis, the production of red blood cells, through stimulation of erythropoietin and direct effects on bone marrow. This is established physiology. Studies show hematocrit rises in a meaningful portion of men on TRT. Coviello et al. (2008, Journal of Clinical Endocrinology and Metabolism) found dose-dependent increases in hematocrit with testosterone, with rates of erythrocytosis climbing significantly at higher doses. The Testosterone Trials (Snyder et al., 2016, New England Journal of Medicine) confirmed hematocrit elevation as one of the more consistent adverse effects across age groups.

However, the claim that "even the smallest amount" causes this in essentially everyone overstates the evidence. Risk is dose-dependent and varies considerably by individual, delivery method, and baseline hematocrit. Topical gels, for instance, tend to produce lower hematocrit increases than injectable cypionate or enanthate at equivalent replacement doses.

What did they get wrong (or right)?

Credit where it is due: the creator is right that elevated hematocrit is a real clinical concern on TRT, that physicians do monitor it, and that it can lead to treatment suspension. Those points align with standard clinical practice guidelines from the American Urological Association and the Endocrine Society.

What they got wrong: the framing that this is a "big fucking lie" doctors hide from patients is simply inaccurate. Hematocrit monitoring is explicitly part of TRT guidelines. It is not suppressed information. Physicians check it because the evidence tells them to, not despite it.

More problematic is the supplement claim. Hemophilol is not a peer-reviewed intervention. The ingredients are not named in the video, so there is no way to evaluate the "clinically shown" assertion directly. Compounds like nattokinase or garlic extract have some blood viscosity data behind them, but none at a regulatory or clinical trial level that supports the kind of comprehensive claim made here, covering thickness, circulation, blood pressure, clotting, and hematocrit simultaneously. That is a pharmacological breadth that no supplement has demonstrated in robust trials.

What should you actually know?

If you are on TRT, hematocrit monitoring is non-negotiable and your prescribing clinician should already be doing it. Hematocrit above 54 percent is the threshold most guidelines use for intervention, which may include dose reduction, switching delivery method, or therapeutic phlebotomy.

No supplement has been validated as a replacement for those clinical interventions. Therapeutic phlebotomy, which simply means donating blood or having blood drawn, is a low-cost, evidence-backed way to manage elevated hematocrit in TRT patients. Fernandez-Balsells et al. (2010, Annals of Internal Medicine) reviewed adverse effects of testosterone therapy and noted erythrocytosis as manageable through dose adjustment and phlebotomy, not supplementation.

If your hematocrit is running high on TRT, the correct move is a conversation with your prescriber, not adding an unvalidated supplement to your stack. The supplement may not harm you, but treating a measurable lab abnormality with a product that has no clinical trial data is not a sound medical strategy. Spending money on Hemophilol while avoiding a frank conversation with your doctor about dose adjustment is exactly backwards.

• Monitor hematocrit every three to six months on TRT, per Endocrine Society guidelines.
• Delivery method matters: injectable testosterone typically causes greater hematocrit elevation than topical formulations.
• If hematocrit exceeds 54 percent, discuss dose reduction or phlebotomy with your clinician before adding supplements.
• No commercial supplement has FDA clearance or robust Phase III trial data for managing TRT-related erythrocytosis.